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Purpose: Knee osteoarthritis (OA) is a common disease, imposing a great burden through pain 
and decreased function. There are many therapeutic modalities including non-pharmacologic 
choices and oral, topical, and intra-articular medications. New studies have shown promising 
results for ozone application in knee OA. Our aim was to compare the effects of ozone therapy 
versus hyaluronic acid (HA) intra-articular injection in knee OA patients.
Methods: In this randomized clinical trial, a total of 174 patients with more than 3 months of 
chronic pain or swelling in the knee joints along with consistent imaging findings were enrolled 
and randomly allocated into two groups of HA and ozone, which were planned to undergo 
3 weekly injections of HA (Hyalgan®) and 10 mL of a 30 µg/mL ozone solution, respectively. 
Patients were evaluated at baseline and 6 months after the last injection for pain, stiffness, and 
function using the visual analog scale (VAS) and the Western Ontario and McMaster Universi-
ties Arthritis Index (WOMAC) questionnaire. 
Results: No major adverse events were detected in this study. Total WOMAC score decreased from 
40.8±9.8 to 20.4±4.9 (p<0.01) in the ozone group and from 38.5±7.9 to 17.1±4.2 (p<0.01) in the 
HA group. A similar trend was observed in pain improvement according to VAS. Pain, stiffness, 
and function significantly improved in both the groups, but no between-group difference was found.
Conclusion: Although both ozone and HA can be effectively used for improving function 
and reducing pain in selected knee OA patients, neither of the two showed any superiority at 
6-month follow-up.
Keywords: ozone, hyaluronic acid, knee osteoarthritis
Plain language summary
 Knee osteoarthritis (OA) is a prevalent disease with many heterogeneous therapeutic 
choices. The only definite treatment is surgery, which is reserved for advanced stages. For 
those who are not candidates for surgery or if symptoms persist after non-invasive options, 
various intra-articular injections are available. Among them, corticosteroids, dextrose, 
normal saline, platelet-rich plasma (PRP), ozone, and hyaluronic acid (HA) are the most 
commonly used ones. Earlier studies have demonstrated inconsistent results with a small 
preference toward PRP and HA injections. Our aim in this trial was to discuss efficacy and 
safety of ozone intra-articular injection in mild to moderate knee OA patients, compared 
to HA (which is a well-known intra-articular supplement and its modest effects have been 
previously proved).
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Introduction
Knee osteoarthritis (OA) is a progressive degenerative condi-
tion in which functional impairment is caused by mechani-
cal forces against the joint, resulting in pain and decreased 
range of motion. Obese women above 50 years of age are 
the most vulnerable group.1 OA was the fourth most com-
mon cause of hospitalization in 2009 in the United States 
with a total cost of $42.3 billion per year.2 The prevalence 
of disease varies highly among different populations: from 
19.3% in some rural areas of Iran to 2.8% in the Philippines. 
Approximately 43% of Iranian adults within the age of 
50–60 years show radiographic findings of knee OA,3 which 
is far more prevalent than in the population of Framingham 
in Massachusetts (19%).4 Most common symptoms of OA 
include pain, stiffness, swelling, and crepitus, and it can 
occasionally lead to joint and limb deformity. Diagnosis is 
mainly based on this clinical picture.5,6 There is no unique 
cure for knee OA; however, there are several treatments such 
as acetaminophen, oral non-steroidal anti-inflammatory 
drugs (NSAIDs), topical creams, patches, and so on, which 
can help to achieve better pain management and higher 
mobility. Although these drugs have been proven to be help-
ful in short-term, evidence showing that such interventions 
could alter the degenerative process exist.7,8 Other comple-
mentary products such as glucosamine and chondroitin are 
also commonly used despite equivocal efficacy.9 Moreover, 
there are many non-pharmacologic choices that can relieve 
the patient’s symptoms, including exercise, shoe modifica-
tion, assistive devices, laser, biofeedback and some physical 
agent modalities.10 The only definite treatment is surgery 
which is reserved for advanced stages.6 For those who are 
not a candidate for surgery or if symptoms persist after non-
invasive options, various intra-articular injections are avail-
able. Among them, corticosteroids, dextrose, prolotherapy, 
normal saline (NS), platelet-rich plasma (PRP), ozone, and 
hyaluronic acid (HA) are the most commonly used.8,11–17 The 
latter is a natural mucopolysaccharide in the synovial joints, 
which might be destroyed secondary to knee OA.14 From a 
biochemical point of view, HA injection has an augmentative 
viscoelastic function and anti-inflammatory effect; hence, it 
has become a widespread topic of interest for non-surgical 
clinical trials.14,16,18
Although the precise physiologic events activated by 
intra-articular injection of HA are still unclear, there is a 
large body of evidence that has confirmed HA efficacy in the 
management of knee OA.8,12,14,19–26 Since the 1990s, HA had 
been proven to be more effective than oral NSAID alone; it 
was also approved in knee OA treatment by the US  Food and 
Drug Administration in 1997.27 It has been well documented 
that HA injection is more effective in earlier stages of OA than 
in advanced disease.14,28 In 2013, a meta-analysis compared 
intra-articular injection of steroids and HA in patients with 
knee OA. They finally concluded that 3–5 weekly injections 
of HA would have a more persistent effect (up to 1 year) than 
corticosteroid injections (2–3 weeks).29 In addition, it should 
be noted that no major complication has been reported for 
HA injection.14,21,23
Another injectable material is ozone gas. There is some 
new evidence supporting the role of ozone injection in the 
management of knee OA symptoms. This gas is now avail-
able in a solution of oxygen ozone.6,30,31 In the last decades, 
many orthopedic centers in Europe have begun to treat knee 
OA patients with intra-articular or peri-articular ozone insuf-
flation.32 Oxygen-ozone solution (O
2
-O
3
) can improve tissue 
oxygenation and inhibit inflammatory mediators mediated by 
the down-regulation of  TNFα and TNF
R2
. Ozone therapy can 
also induce a moderate-intensity oxidative stress and inhibit 
inflammatory responses.30,31,33,34 Ozone also has a relatively 
moderate analgesic effect through phosphodiesterase A2 
blockage.6 According to another study, oxygen-ozone injec-
tion could induce some histological changes in the joint and 
consequently lead to pain killing effects.35 Although the present 
data suggest that ozone causes neither acute nor chronic toxic-
ity,31,32 there is an increased risk of some complications such 
as septic arthritis (SA) in any invasive articular procedure.36
Many randomized clinical trials have confirmed the efficacy 
and safety of ozone therapy in the management of lumbosacral 
disc herniation, failed back surgery syndrome, and shoulder 
disorders.31,37–40 Moreover, ozone has a good effect in managing 
symptoms after traumatic meniscal injuries.41 In 2011, Mishra 
et al reported a remarkable superiority in the use of ozone 
compared to steroid intra-articular injection in 46 knee OA 
patients during a 6-month follow-up. Ozone success rate was 
90% after 6 months based on Western Ontario and McMaster 
Universities Arthritis Index (WOMAC).6 Considering the high 
costs and existing uncertainty, our aim in this study was to 
compare intra-articular ozone and HA safety and efficacy in 
improvement of pain, range of motion (ROM) and functional 
score among patients with knee OA in a 6-month follow-up.
Methods
This double-blind randomized clinical trial was conducted 
in the Physical medicine and rehabilitation (PM&R) clinic 
of Shahid Modarres Hospital in Tehran from January 2015 
to January 2016. A written informed consent was obtained 
from each participant. This study was approved by the ethics 
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committee of the Shahid Beheshti University of Medical Sci-
ences, Tehran, Iran (No: IR.SBMU.RETECH.REC.1396.237) 
and also retrospectively registered in Iranian Registry of 
Clinical Trials Database (IRCT; IRCT2017041513442N16). 
Inclusion criteria
All patients with the following conditions were included: 
aged between 45 and 75 years, symptomatic knee OA with the 
pain aggravated by weight bearing and symptoms lasting for 
at least 6 months despite conservative treatments. For patients 
with bilateral symptoms, injection was administered on the 
more symptomatic limb. Subjects were screened using the 
Kellgren–Lawrance radiologic scoring (KLS) system (scores 
ranging from 0 to 4 grades) and patients with a consistent 
radiographic KLS score of 2–3 were included.6
Exclusion criteria
Our exclusion criteria were history of trauma, surgery or 
any invasive procedure in the affected joint during the past 
6 months, malalignment in lower limbs, and abnormal blood 
count or impaired coagulation tests. We also excluded preg-
nant women, patients who were under immunosuppressant 
treatments or those with an underlying systemic arthropathy 
(secondary OA). In addition, patients being treated with 
angiotensin-converting enzyme inhibitors (ACEI) and those 
with significant deficiency in glucose 6-phosphate dehydro-
genase level were excluded.21,31
Interventions
Using an Ozomed® smartline machine (Kastner-Praxisbedarf 
GmbH, Medizintechnik, Germany), 10 cc of ozone was 
injected into the affected knee joint of patients in the ozone 
group as an oxygen-ozone solution with the precise con-
centration of 30 µg/mL. For the subjects in HA group, HA 
was injected as a 20 mg/2 mL solution of HA (Hyalgan®, a 
viscous product with a molecular weight of 500–730 kDa, 
containing purified natural hyaluronate in sodium chloride 
solution; Fidia Farmaceutici S.p.A., Abano Terme, Italy). 
Before injecting the main product, 2 cc of lidocaine 2% solu-
tion was injected in all patients, using a 22-G needle, through 
the classic approach (anteromedial in flexed knee position) in 
supine position and 90° flexion of knee under sterile condi-
tions. In both groups weekly injections were performed for 
3 consecutive weeks by a specialist physician in PM&R with 
a 15-year experience in the musculoskeletal injections’ field. 
It should be noted that the latter physician was not blinded 
because of the totally different nature of ozone and HA; 
however, patients and the examiner physician were blinded.
Ice pack application and having relative rest up to 48 
hours after injection were advised to patients in both the 
groups, if needed. Patients were advised to implement 
lifestyle modification with regard to knee activities. Also 
participants were instructed to perform regular therapeutic 
exercise including hamstring stretching, as well as isotonic 
and multi-angular isometric quadriceps strengthening. In 
addition, one of the authors (senior PM&R resident) was 
responsible for monthly overseeing of exercise and lifestyle 
modification (including using elevator instead of stairs and 
avoiding squatting, contact sports, and so on) performance. 
Outcome measurements
Patients were evaluated before treatment and 6 months after 
injections. Their pain and functional scores were assessed 
during an interview by a blinded senior medical resident 
using the visual analog scale (VAS) and Persian version 
of the WOMAC questionnaire. Primary evaluation of pain 
was performed with VAS (scale of 0–10, 0 for no pain and 
10 means the worst pain ever).42 Secondary evaluation was 
done using WOMAC, with scores ranging from 0 to 4 (0= no 
pain/restriction, 1= mild pain/restriction, 2= moderate pain/
restriction, 3= severe pain/restriction, and 4= very severe 
pain/restriction). The maximum scores for pain, stiffness, 
and physical function and total WOMAC were 20, 8, 68 and 
96, respectively. It is scored on a Likert scale; lower total 
scores mean less symptoms and better function.43 All patients 
underwent three weekly injections and were finally evaluated 
6 months after their last injection. 
Data analysis
GPower software was used to estimate the sample size. The 
minimum number for each group was calculated as 65 (based 
on α=0.05 and β=0.2), and with the assumption of a 20% 
drop rate, we recruited 87 patients in each group. Analysis 
was done using Statistical Package for the Social Sciences 
(version 22.0; IBM Corporation, Armonk, NY, USA) by 
means of paired t-test and chi square test for quantitative and 
qualitative variables, respectively. The difference between 
efficacies of the two therapeutic methods was described as 
effect size (raw mean difference [RMD]) and analyzed using 
Mann–Whitney U test. A p-value <0.05 was considered as 
statistically significant.
Results
This randomized control trial (RCT) was conducted in Sha-
hid Modarres Hospital from January 2015 to January 2016 
in patients with primary knee OA who presented to PM&R 
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clinic. A total of 174 consecutive participants who were 
eligible with regard to inclusion criteria were enrolled and 
then randomly divided into two groups using a computer-
based randomization method; 87 persons in each of the 
ozone and HA groups. Despite their initial agreement with 
the study protocol and random allocation, 10 patients left 
the study because of dissatisfaction on concealed allocation. 
The study commenced with the remaining 164 participants, 
of whom 141 continued the study till the end, including 67 
patients in the ozone group and 74 subjects in the HA group 
(Figure 1). Data gathered from the 23 participants who left 
the study were not analyzed. The reasons for their departure 
were personal problems or choosing other treatments and 
not occurrence of any complications or side effects related 
to the injections.
Before treatment, both the groups were nearly similar 
with no significant difference in their demographic, anthro-
pometric, or clinical variables (Table 1).
Based on our findings, the two treatments had been proven 
to be effective in improving functional score and reducing 
pain and stiffness in knee primary OA patients: WOMAC 
score in the ozone group decreased from 40.8 to 20.4 at 
6-month follow-up (RMD =−20.4, p<0.01) and in the HA 
group, it decreased from 38.5 to 17.1 (RMD =−21.4, p<0.01). 
A similar trend was observed for VAS improvement; RMD 
=−5.0, p<0.05 in the ozone group and RMD =−4.1, p<0.05 
in the HA group (Table 2).
Within three parts of the WOMAC questionnaire, the 
maximum amount of improvement for both the methods 
was observed in pain and stiffness. Although there was no 
statistical difference between the two therapeutic methods, 
improvement in VAS and two parts of WOMAC (pain and 
stiffness) was slightly better after ozone injection than for 
HA. But in total WOMAC score, the functional part was 
better for HA injection. However, the comparative analysis 
of the two treatments showed no significant difference in 
any of the clinical scores, at the 6-month follow-up, possibly 
due to small effect size or lack of a big enough sample size. 
Moreover, no major complications occurred in either of the 
two groups. The only adverse event was a mild flare reaction 
after the first injection, which was observed in five patients 
(two participants in the HA group and three in the ozone 
group). There was no statistical difference between the two 
groups regarding their post injection flare reactions.
Figure 1 Flow diagram of the study population.
Abbreviation: HA, hyaluronic acid.
198 patients were assessed
for eligibility 
24 persons were 
excluded
174 patients were
enrolled 
87 participants in ozone group:
81 patients accepted concealed
allocation and six did not accept 
Six participants left due to
personal problems.
One patient went into
surgery during follow-up
period
Two chose other
treatments
74 patients were analyzed
87 participants in HA group:
83 patients accepted concealed
allocation and four did not accept 
Eight patients left due to
personal problems.
Five participants quit 
because they chose other
conservative treatments
A patient left due to family
immigration
67 participants were analyzed
Enrollment
Allocation
Follow-up
Analysis
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Discussion
Our main objective in this RCT was to compare the efficacy 
and safety of ozone intra-articular injection versus the vis-
cosupplement products in the management of pain and other 
OA symptoms in patients with mild to moderate knee OA.
There are several similar studies on short-term effects 
of ozone intra-articular injection.35,44 Some studies detected 
an obvious post injection decline in cytokines responsible 
for inflammation and OA progression.45 In an Indian study, 
researchers performed a cross-over study with two therapeu-
tic methods in 46 patients with knee OA; a single injection of 
methyl-prednisolone versus three monthly ozone injections. 
After 6 months, the researchers observed an 80% response 
rate in the ozone group versus 60% in the steroid group.6 
Other studies reported that ozone intra-articular injection 
had beneficial effects equal to that of hypertonic dextrose and 
was more effective than just air injection in the management 
of knee OA symptoms.39,46 Another trial in 2014 compared 
ozone and HA efficacy in two groups of 30 participants with 
knee OA. They finally found a strong improvement in both 
the groups compared to baseline; however, there were no 
significant differences between the two methods during a 
short-term follow-up.25
In all the previous studies that had compared ozone 
versus HA intra-articular injections, both the methods had 
been proven to be efficient in the management of pain and 
other symptoms; however, there are controversial results 
with regard to duration of pain-free period and effect size of 
each method. Longer follow-up like in an RCT performed in 
2015 in Turkey which followed 102 patients in three groups 
(ozone, HA, and PRP) demonstrated a more persistent effect 
for HA compared to ozone.21 Another similar study with three 
groups of ozone, HA, and combination therapy found a higher 
improvement in clinical scores for the combination therapy 
compared to the two other groups in the 2-month  follow-up.34 
Also as mentioned before, authors in the Turkish study finally 
concluded that HA was more successful than ozone injection 
after the third-month follow-up. In contrast to our results, 
patients undergoing HA injection in that study showed a 
longer asymptomatic period, compared to the ozone group;21 
whereas there are some studies with results similar to ours 
which have shown no significant difference between ozone 
and HA.6 Hence, according to the current study, although 
there was a considerable improvement in both the groups, 
no significant differences were observed in the efficacy and 
safety of the two methods.
Table 1 Demographic distribution and comparison of clinical variables in the two groups before treatment
Group Patients, n Age (years)
± SD
Gender
(F:M)
BMI (kg/m2)
± SD
WOMAC
± SD
VAS
± SD
OA grade 
(II:III)
Ozone 67 58.1±6.4 50:17
(75%:25%)
26.8±1.95 40.8±9.0 7.6±2.8 37:30
(56%:44%)
HA 74 61.1±6.3 56:18
(77%:23%)
28.6±1.65 38.5±8.0 7.1±3.2 40:34
(54%:46%)
p-value – 0.44 0.88 0.08 0.16 0.86 0.80
Abbreviations: SD, standard deviation; F, female; M, male; BMI, body mass index; WOMAC, Western Ontario and McMaster Universities Arthritis Index; VAS, visual analog 
scale; OA, osteoarthritis; HA, hyaluronic acid.
Table 2 VAS and WOMAC scores of the HA and ozone groups at the 6th month after injection
Measure Ozone therapy
Before
Mean ± SD
After Raw mean
difference (SE)
[95 % CI]
HA therapy
Before
Mean ± SD
After Raw mean
difference (SE)
[95%CI]
VAS 7.6±2.8 2.6±2.0
−5.0 (0.2)
[4.6–5.4] 
7.1±3.2 3.0±2.4 −4.1(0.15)
[3.8–4.4]
WOMAC
Pain
9.3±4.4 3.2±1.6 −6.1 (0.2)
[5.7–6.5] 
8.8±4.0 2.9±1.6 −5.9 (0.2)
[5.5–6.3]
WOMAC
Stiffness
2.3±2.4 1.1±1.6 −1.2 (0.05)
[1.1–1.3]
2.1±1.6 1.1±0.8 −1.0 (0.05)
[0.9–1.1]
WOMAC
Function
29.2±7.0 16.1±4.2 −13.1 (0.15)
[12.8–13.4] 
27.6±6.6 13.1±3.2 −14.5 (0.3)
[13.9–15.1]
WOMAC
Total
40.8±9.0 20.4±5.0 −20.4 (0.2)
[20.0–20.8]
38.5±8.0 17.1±4.2 −21.4 (0.2)
[21.0–21.8]
Abbreviations: SE, standard error of mean; SD, standard deviation; CI, confidence interval; HA, hyaluronic acid; WOMAC, Western Ontario and McMaster Universities 
Arthritis Index; VAS, visual analog scale; OA, osteoarthritis; HA, hyaluronic acid.
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Limitations
One of the most important limitations of our study was 
the single follow-up session, from which we could not 
estimate the time of onset for the therapeutic effects. The 
second shortcoming was not assessing the exact physical 
activity level in patients before and after intra-articular 
injections; this variable definitely could affect the amount 
of improvement and duration of symptom-free period. In 
addition, as another limitation, the current trial did not 
evaluate patients’ overall satisfaction as a final important 
variable. Future studies should strongly emphasize evaluat-
ing satisfaction, longer follow-up periods, larger sample 
size, matching physical activity level, and considering 
more objective outcome measures like magnetic resonance 
imaging to better clarify possible histologic changes in the 
articular surface.
Conclusion
Based on our results, although both ozone and HA can be 
effectively used for improving function, pain, and ROM in 
selected knee OA patients, neither of the two showed any 
superiority at 6-month follow-up. Improvement in all our 
outcome measures was quite similar between the two groups, 
and it seems appropriate to conclude that ozone injection can 
result in sufficient symptom relief (particularly in pain and 
stiffness) by at least 6 months. Hence, considering availabil-
ity, accessibility, and cost–benefit trade-off, clinicians could 
make a choice between these intra-articular injections for 
each individual patient.
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